These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 2693128)

  • 21. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant erythropoietin and chronic renal failure.
    Lundin AP
    Hosp Pract (Off Ed); 1991 Apr; 26(4):61-9. PubMed ID: 2010480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anemia and erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis.
    Korbet SM
    Kidney Int Suppl; 1993 Feb; 40():S111-9. PubMed ID: 8445832
    [No Abstract]   [Full Text] [Related]  

  • 24. Erythropoietin for the anemia of chronic renal failure.
    Schwartz AB; Prior J; Terzian L; Kahn B
    Am Fam Physician; 1988 Jun; 37(6):211-5. PubMed ID: 3289343
    [No Abstract]   [Full Text] [Related]  

  • 25. [The importance of erythropoietin in the therapy of anemia in patients on chronic hemodialysis].
    von Appen K; Klinkmann H
    Urol Nefrol (Mosk); 1990; (6):69-70. PubMed ID: 2089771
    [No Abstract]   [Full Text] [Related]  

  • 26. Renal anemia: from incurable to curable.
    Sato Y; Yanagita M
    Am J Physiol Renal Physiol; 2013 Nov; 305(9):F1239-48. PubMed ID: 23884144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Erythropoietin: from established therapeutic procedures in renal anemia to future areas of use].
    Marsen TA; Pollok M; Baldamus CA
    Med Klin (Munich); 1992 Apr; 87(4):207-14. PubMed ID: 1579099
    [No Abstract]   [Full Text] [Related]  

  • 28. Erythropoietin: from mountain top to bedside.
    Erslev AJ; Caro J
    Adv Exp Med Biol; 1989; 271():1-7. PubMed ID: 2486278
    [No Abstract]   [Full Text] [Related]  

  • 29. [Factors limiting the correction of anemia with recombinant human erythropoietin].
    Casati S
    Minerva Urol Nefrol; 1991; 43(3):121-3. PubMed ID: 1817332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of anemia caused by chronic kidney failure in adults].
    Nephrol Ther; 2005 Aug; 1 Suppl 1():S1-48. PubMed ID: 16895707
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of erythropoietin administration in uremia.
    Gurland HJ; Samtleben W; Schmidt B
    Contrib Nephrol; 1989; 70():172-7. PubMed ID: 2670428
    [No Abstract]   [Full Text] [Related]  

  • 32. Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.
    Binkley LS
    Transplant Proc; 1991 Apr; 23(2):1831-2. PubMed ID: 2053169
    [No Abstract]   [Full Text] [Related]  

  • 33. Strategies to optimize the use of erythropoietin and iron therapy in oncology patients.
    Ford PA; Mastoris J
    Transfusion; 2004 Dec; 44(12 Suppl):15S-25S. PubMed ID: 15585001
    [No Abstract]   [Full Text] [Related]  

  • 34. Benefits and concerns of treating pre-dialysis and renal transplant patients with recombinant human erythropoietin.
    Vanrenterghem Y; Vanwalleghem J
    Nephrol Dial Transplant; 1998; 13 Suppl 2():13-5. PubMed ID: 9566485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Erythropoietin-Stimulating Agents (ESA) in Patients With End-Stage Renal Failure Decided to Forego Dialysis: Palliative Perspective.
    Cheng HW; Chan KY; Lau HT; Man CW; Cheng SC; Lam C
    Am J Hosp Palliat Care; 2017 May; 34(4):380-384. PubMed ID: 26718957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erythropoietin after bone marrow transplantation.
    Miller CB; Mills S
    Hematol Oncol Clin North Am; 1994 Oct; 8(5):975-92. PubMed ID: 7852219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. rHuEpo before dialysis and in dialysed patients.
    López-Gómez JM; Jofre R; Moreno F; Verde E; Valderràbano F
    Nephrol Dial Transplant; 1995; 10 Suppl 6():31-5. PubMed ID: 8524491
    [No Abstract]   [Full Text] [Related]  

  • 38. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.
    Rainville N; Jachimowicz E; Wojchowski DM
    Expert Opin Ther Targets; 2016; 20(3):287-301. PubMed ID: 26419263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The modality of dialysis treatment: does it influence the response to erythropoietin treatment?
    Locatelli F; Del Vecchio L; Andrulli S
    Nephrol Dial Transplant; 2001 Oct; 16(10):1971-4. PubMed ID: 11572880
    [No Abstract]   [Full Text] [Related]  

  • 40. Should target hemoglobin levels in dialysis patients be lowered to 9-10 g/dl?
    Fishbane S; Masani NN; Hazzan AD
    Semin Dial; 2014; 27(3):282-4. PubMed ID: 24666175
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.